Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Cancer Lett. 2022 Jul 22;545:215832. doi: 10.1016/j.canlet.2022.215832

Fig 3. Overexpression of PPAR resulted in reduced activity of lenalidomide in vitro.

Fig 3.

(A). NCIH929 and RPMI8226 cell lines were transfected with control vector or a PPAR over-expressing plasmid for 24h and then treated with lenalidomide for additional 48h. Cell viability was measured by MTT assay. (B). NCIH929 and RPMI8226 cell lines were transfected with control vector or a CRBN over-expressing plasmid for 24h and then treat with lenalidomide alone or in combination with PPAR agonists for 48h. Cell viability was measured by MTT assay. (C). NCIH929 and RPMI8226 cells were transduced with CRBN specific CRISP/cas9 knockout plasmid for 24h and then treated with lenalidomide, PPAR agonists alone, or in combination for additional 48h. Cell viability was measured by MTT assay. Results are presented as mean ± SD from at least three separate experiments. *: p<0.05; **: p<0.01; ***: p<0.001.